Siemens Healthineers AG (ETR:SHL)
Germany · Delayed Price · Currency is EUR | Market Cap | 43.56B -17.1% |
| Revenue (ttm) | 23.17B -0.9% |
| Net Income | 2.21B +1.9% |
| EPS | 1.97 +2.3% |
| Shares Out | 1.11B |
| PE Ratio | 19.82 |
| Forward PE | 17.34 |
| Dividend | 1.00 (2.50%) |
| Ex-Dividend Date | Feb 6, 2026 |
| Volume | 677,952 |
| Open | 39.54 |
| Previous Close | 39.52 |
| Day's Range | 39.13 - 39.64 |
| 52-Week Range | 32.81 - 49.71 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 45.15 (+15.39%) |
| Earnings Date | Nov 5, 2026 |
About Siemens Healthineers AG
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers in Germany, the United States, rest of Europe, CIS, Africa, the Middle East, the Americas, the Asia Pacific, Japan, and China. It operates in four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment offers magnetic resonance imaging, computed tomography, X-ray, molecular imaging, and ultrasound systems; and software solutions to support the readin... [Read more]
Financial Performance
In fiscal year 2025, Siemens Healthineers AG's revenue was 23.38 billion, an increase of 4.53% compared to the previous year's 22.36 billion. Earnings were 2.14 billion, an increase of 10.40%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for SHL stock is "Buy." The 12-month stock price target is €45.15, which is an increase of 15.39% from the latest price.
News
Siemens Healthineers Q3 Earnings Call Highlights
Siemens Healthineers ETR: SHL lowered its fiscal 2026 revenue growth outlook after continued weakness in its Diagnostics business, while raising its adjusted earnings-per-share guidance to reflect tar...
Siemens Healthineers AG Earnings Call Transcript: Q3 2026
Q3 delivered strong equipment orders and solid growth in Imaging and Precision Therapy, but Diagnostics continued to decline, especially in China. Revenue guidance for FY2026 was lowered, while EPS guidance was raised due to tariff refunds. Robust order book and innovation support future growth.
Siemens Healthineers AG Earnings release: Q3 2026
Siemens Healthineers AG released its Q3 2026 earnings on July 31, 2026, summarizing the period's financial results.
Siemens Healthineers AG Slides: Q3 2026
Siemens Healthineers AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on July 31, 2026.
Siemens Healthineers Cuts Revenue Outlook on Diagnostics Weakness
The German supplier of medical equipment now expects fiscal-year revenue to grow by between 3.5% and 4.0% on a comparable basis, compared with 4.5% to 5% previously.
Siemens Healthineers cuts revenue forecast citing diagnostics weakness
Medical technology firm Siemens Healthineers cut its 2026 revenue growth forecast on Friday to a range of 3.5% to 4.0%, as China's procurement policy weighs on its diagnostics business.
Siemens Healthineers AG Transcript: Pre-close call
Q3 is expected to see mid-single digit Imaging growth, margin declines in key segments due to FX and inflation, and easing tariff headwinds. Diagnostics faces a smaller revenue drop and sequential margin improvement from cost actions.
Siemens Healthineers AG Transcript: Status update
Imaging and advanced therapies showed strong momentum, while diagnostics faced significant headwinds in China but is expected to stabilize within two quarters. Strategic carve-out preparations for diagnostics are underway, with innovation and cost management supporting future growth.
AiM Medical Robotics Announces Collaboration Agreement with Siemens Healthineers to Advance MRI-Guided Robotic Neurosurgery
Worcester, MA, May 26, 2026 (GLOBE NEWSWIRE) -- AiM Medical Robotics, a leading developer of advanced robotic systems for MRI-guided neurosurgery, today announced a collaboration agreement with Siemen...
Siemens Healthineers AG Earnings Call Transcript: Q2 2026
Imaging and precision therapy segments delivered strong growth and margin expansion in Q2 FY2026, offsetting significant FX and tariff headwinds, while Diagnostics faced revenue and margin declines due to China market challenges. FY2026 guidance was revised lower, but midterm double-digit EPS growth ambition remains intact.
Siemens Healthineers AG Slides: Q2 2026
Siemens Healthineers AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 7, 2026.
Siemens Healthineers AG Earnings release: Q2 2026
Siemens Healthineers AG released its Q2 2026 earnings on May 7, 2026, summarizing the period's financial results.
Siemens Healthineers AG Quarterly report: Q2 2026
Siemens Healthineers AG has published its Q2 2026 quarterly earnings report on May 7, 2026.
Siemens Healthineers cuts 2026 outlook
Siemens Healthineers on Thursday cut its full year outlook to forecast revenue growth of between 4.5% and 5.0% for the 2026 financial year due to weakness in China's diagnostics market and high...
CDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results
Tarrytown, NY, USA, May 04, 2026 (GLOBE NEWSWIRE) -- Siemens Healthineers announced its Atellica IM Testosterone II (TSTII) assay has achieved certification through the Centers for Disease Control and...
Siemens plans shareholder vote on Siemens Healthineers spin-off in February 2027
Siemens said on Friday it planned a shareholder vote on a direct spin-off of Siemens Healthineers shares at its next shareholder meeting in February 2027.
Siemens Healthineers AG Transcript: Pre-close call
Q2 revenue growth is expected below the 5%-6% outlook, with significant FX and tariff headwinds impacting margins and EBIT. Diagnostics faces pronounced declines in China, while hedging and pricing strategies aim to offset cost inflation risks.
Imaginostics Receives Siemens Healthineers Letter of Support as Companies Advance Quantitative MRI Dialogue
ORLANDO, Fla.--(BUSINESS WIRE)-- #Alzheimers--Imaginostics, Inc. today announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions r...
Siemens Healthineers Launches Brain Health Research Portfolio with First Biomarker Assays Now Available
Brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays now available for research use Brain-derived, fully automated Atellica IM P...
Ki Reply and Data Reply Lay the Strategic Foundation for AI Innovation at Siemens Healthineers with “Cerebra”
TURIN, Italy--(BUSINESS WIRE)--Ki Reply and Data Reply, the Reply Group companies specialised respectively in AI-powered software development and data-driven solutions, have partnered with the “CRM Ex...
Siemens Healthineers AG Transcript: Status update
Imaging and Precision Therapy delivered strong growth and margins, offsetting Diagnostics' decline due to China market headwinds. H2 is expected to improve with cost reductions, core lab momentum, and new product launches, while spin-off preparations advance.
Siemens Healthineers Core Businesses Offset Currency, Tariff Challenges
Revenue grew on a comparable basis as results in its imaging and precision therapy business units offset currency and tariff headwinds.
Siemens Healthineers AG Earnings Call Transcript: Q1 2026
Imaging and precision therapy segments delivered strong growth and margin expansion, offsetting diagnostics challenges in China, while group revenue rose 3.8% year-over-year. Fiscal 2026 outlook is confirmed, with tariffs and FX as key headwinds but operational improvements continuing.
Siemens Healthineers AG Earnings release: Q1 2026
Siemens Healthineers AG released its Q1 2026 earnings on February 5, 2026, summarizing the period's financial results.
Siemens Healthineers AG Slides: Q1 2026
Siemens Healthineers AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on February 5, 2026.